Humacyte, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $HUMA in the last 30 days.
See all $HUMA insider activity →Humacyte Inc. (HUMA) reported positive interim results from its V012 Phase 3 trial for a hemodialysis access device, showing superiority over the current standard. The trial was stopped early after meeting its primary endpoint. The company plans to submit an FDA application to expand the device's label. HUMA's stock may be of interest to investors.
Humacyte Inc. (NASDAQ:HUMA) reported 15 new hospital orders for its Symvess product, bringing the total to 49. H.C. Wainwright reiterated a Buy rating and $4.00 price target, citing commercial momentum. The company's stock trades at $0.44, with a 52-week high of $1.90. Revenue grew 159% over the last year, but Q2 earnings missed estimates. Humacyte maintains a market cap of $122 million and a strong current ratio of 6.21.
Humacyte (HUMA) reported a 44% increase in hospitals ordering its vascular trauma product Symvess, rising to 49 from 34 in Q2 2026. The company expects to exceed its goal of adding 20 new hospitals by year-end. Symvess is FDA-approved for urgent revascularization in adults. Humacyte is also developing other vascular applications.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning HUMA (Humacyte, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent HUMA coverage spans insider activity, technology and financial news.
Positive trial data suggests strong clinical advantage and potential market adoption for Humacyte's dialysis access device.
New hospital orders suggest commercial momentum, likely supporting the stock price.
The surge in orders indicates accelerating commercial traction and may boost near‑term revenue forecasts.
Potential label expansion could significantly increase market opportunity and drive share price higher.
Board expansion may improve governance and execution of upcoming product launches.
AlphAI scores every news story that mentions HUMA with an AI model for sentiment and relevance, and aggregates insider trades from Humacyte, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Humacyte Inc. (HUMA) reported positive interim results from its V012 Phase 3 trial for a hemodialysis access device, showing superiority over the current standard. The trial was stopped early after meeting its primary endpoint. The company plans to submit an FDA application to expand the device's label. HUMA's stock may be of interest to investors.
2 min readHumacyte Inc. (NASDAQ:HUMA) reported 15 new hospital orders for its Symvess product, bringing the total to 49. H.C. Wainwright reiterated a Buy rating and $4.00 price target, citing commercial momentum. The company's stock trades at $0.44, with a 52-week high of $1.90. Revenue grew 159% over the last year, but Q2 earnings missed estimates. Humacyte maintains a market cap of $122 million and a strong current ratio of 6.21.
2 min readHumacyte (HUMA) reported a 44% increase in hospitals ordering its vascular trauma product Symvess, rising to 49 from 34 in Q2 2026. The company expects to exceed its goal of adding 20 new hospitals by year-end. Symvess is FDA-approved for urgent revascularization in adults. Humacyte is also developing other vascular applications.
2 min readHumacyte, Inc. (HUMA) plans to submit a supplemental BLA this quarter to expand Symvess's label to AV access for hemodialysis. The company will present interim Phase 3 data for its ATEV at ASN Kidney Week 2026.
2 min readHumacyte, Inc. (HUMA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human
2 min readJones Keith Anthony purchased 10,000 shares of Humacyte, Inc. (HUMA) at $0.56 on 2026-09-14.
1 min readHumacyte Inc. (HUMA) announced that the FDA extended the shelf life of its Symvess product from 18 to 36 months. The decision was based on stability data showing Symvess meets quality standards. The company's CEO noted the extension supports hospital adoption and reduces product waste. HUMA's stock is currently trading at $0.58, down 1.13%.
2 min readJones Keith Anthony purchased 10,000 shares of Humacyte, Inc. (HUMA) at $0.69 on 2026-08-20.
1 min readUltragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readJones Keith Anthony purchased 30,000 shares of Humacyte, Inc. (HUMA) at $0.59 on 2026-08-17.
1 min read
